BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castelo A, Mello CEB, Teixeira R, Madruga JVR, Reuter T, Pereira LMMB, Silva GF, Álvares-DA-Silva MR, Zambrini H, Ferreira PRA. HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE. Arq Gastroenterol 2018;55:329-37. [PMID: 30785514 DOI: 10.1590/S0004-2803.201800000-74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ma J, He L, Chen K, Wang Y, Ren Y, Xing W, Jiang Y. Comparative study on anti-HCV testing using plasma, dried plasma spots (DPS), and dried blood spots (DBS). Biosafety and Health 2021;3:50-5. [DOI: 10.1016/j.bsheal.2020.06.003] [Reference Citation Analysis]
2 Mattingly TJ 2nd, Love BL, Khokhar B. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. Pharmacoeconomics 2020;38:927-39. [PMID: 32533524 DOI: 10.1007/s40273-020-00933-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vivaldini SM, Ribeiro RA, Mosimann Júnior G, Tonini KC, Pereira GFM, Araújo WN. A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil. Braz J Infect Dis 2021;25:101573. [PMID: 33836175 DOI: 10.1016/j.bjid.2021.101573] [Reference Citation Analysis]
4 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Reference Citation Analysis]